<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225312</url>
  </required_header>
  <id_info>
    <org_study_id>NL70503.029.19</org_study_id>
    <nct_id>NCT04225312</nct_id>
  </id_info>
  <brief_title>Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis</brief_title>
  <acronym>NEXT-MS</acronym>
  <official_title>Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting MS Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovatiefonds Zorgverzekeraard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Natalizumab is an effective drug in the treatment for relapsing remitting multiple
      sclerosis (RRMS) and is approved in the treatment regimen of 4-weekly 300mg natalizumab
      infusions. Natalizumab trough concentrations after a 4-weekly interval are high in the large
      majority of patients which implies a relative overdose in most patients. The investigators
      have demonstrated that efficacy of natalizumab is maintained when the infusion interval is
      extended based on natalizumab trough concentrations (personalized extended interval dosing).
      This leads to fewer hospital visits, a decrease of healthcare costs and decrease of risk of
      complications of natalizumab treatment.

      Objective: The objective is to test feasibility and validate safety of personalized extended
      interval dosing of natalizumab in a large real-life cohort across the Netherlands.

      Study design: Prospective national phase IV natalizumab cohort study.

      Study population: All patients, aged 18 years or older, who are currently treated with
      natalizumab in the Netherlands for RRMS, with a minimum of 6 consecutive infusions.

      Intervention: Patients will receive a personalized extended interval dosing (4-8 weeks) based
      on two natalizumab trough concentrations in the standard 4 week interval.

      Main study parameters/endpoints: The main study endpoint is the safety (defined by
      radiological disease activity) of personalized natalizumab dosing in a large real-life cohort
      across the Netherlands. Data will be collected regarding disease activity and disability
      progression. A cost analysis will be performed to show the extent of cost reduction. Patients
      will be annually followed to assess the influence of personalized dosing on John Cunningham
      virus (JCV) conversion, JCV index, incidence of progressive multifocal leukoencephalopathy
      and treatment satisfaction and quality of life. The influence of personalized dosing on
      pharmacokinetics will be monitored. Furthermore, personalized extended interval dosing will
      be studied in a subgroup with the aim to explore lower than previously studied trough values
      of natalizumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">January 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective national phase IV natalizumab cohort study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of T2 lesions on brain MRI</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Assessing new/enlarging T2 lesions on brain MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized relapse rate</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Clinical relapses during personalized extended interval dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability progression during follow-up</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Disability progression measured on the Expanded Disability Status Scale (EDSS); running form 0 (no disability) to 10 (death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Cost-utility analysis using EuroQol 5D (EQ-5D) and the Work Productivity and Activtiy Impairment Questionnaire (WPAI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>JC virus conversion</measure>
    <time_frame>6 monthly JCV measurement for two years</time_frame>
    <description>Annual conversion rate of the John Cunningham Virus (JCV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course JC virus index</measure>
    <time_frame>6 monthly JCV measurement for two years</time_frame>
    <description>Course of John Cunningham Virus (JCV) index in JCV positive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natalizumab wearing-off effect</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Occurrence of the natalizumab wearing-off effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability of natalizumab trough concentration</measure>
    <time_frame>6 monthly natalizumab trough concentrations for two years</time_frame>
    <description>Long-term stability of natalizumab trough concentration in personalized interval dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient preference</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of patients preferring personalized treatment over standard treatment and percentage staying on personalized treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: MSIS-29</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Quality of life on the Multiple Sclerosis Impact Scale (MSIS-29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of treatment: TSQM</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Satisfaction of treatment on the Treatment Satisfaction Questionnaire of Medication (TSQM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive multifocal leukoencephalopathy</measure>
    <time_frame>Trough study completion, an average of 2 years</time_frame>
    <description>Incidence of progressive multifocal leukoencephalopathy</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Personalized extended interval dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Personalized dosing based on natalizumab trough concentration with an aim of natalizumab trough concentration of 10mcg/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Personalized longer extended interval dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Personalized dosing based on natalizumab trough concentration with an aim of natalizumab trough concentration of 5mcg/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard interval dosing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who prefer to stay on standard interval dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Historic cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Historic cohort of natalizumab treated patients on standard interval dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Personalized extended interval dosing of natalizumab</intervention_name>
    <description>Personalized extended interval dosing of natalizumab based on natalizumab trough concentration</description>
    <arm_group_label>Personalized extended interval dosing</arm_group_label>
    <arm_group_label>Personalized longer extended interval dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard interval dosing</intervention_name>
    <description>Standard interval dosing in control group and historic group</description>
    <arm_group_label>Historic cohort</arm_group_label>
    <arm_group_label>Standard interval dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of relapsing remitting multiple sclerosis according to the 2017 criteria21

          -  6 or more consecutive natalizumab infusions

          -  18 years or older

          -  Agreed to participate (written informed consent)

          -  Disease stability (radiological and clinical) ≥ 12 months (only in low personalized
             extended interval dosing group)

        Exclusion Criteria:

          -  High titer natalizumab (&gt;100 arbitrary units (AU)/ml) antibodies

          -  Contraindication for frequent magnetic resonance imaging (MRI) (ie, pacemaker or other
             contraindicated implanted metal devices, or have claustrophobia that cannot be
             medically managed)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joep Killestein</last_name>
    <phone>0031 0204441982</phone>
    <email>j.killestein@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zoé van Kempen</last_name>
    <phone>0031 0204442182</phone>
    <email>z.vankempen@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nynke Kalkers, Dr</last_name>
      <email>n.f.kalkers@olvg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU medical center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joep Killestein</last_name>
      <email>j.killestein@amsterdamumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jop Mostert, Dr</last_name>
      <email>jmostert@rijnstate.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>van Munster</last_name>
      <email>CvanMunster@amphia.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>van Eijk</last_name>
      <email>J.Eijkvan@jbz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Berger-Plantinga</last_name>
      <email>e.bergerplantinga@haaglandenmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Slingeland Hospital</name>
      <address>
        <city>Doetinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roosendaal</last_name>
      <email>C.Roosendaal@slingeland.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ommelander Hospital Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nielsen</last_name>
      <email>j.nielsen@ozg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heersema</last_name>
      <email>d.j.heersema@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>van Dijk</last_name>
      <email>g.v.dijk@cwz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wokke</last_name>
      <email>b.wokke@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elizabeth tweesteden Hospital</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnoldus</last_name>
      <email>e.arnoldus@etz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bouvy</last_name>
      <email>wbouvy@diakhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erwin Hoogervorst, Dr</last_name>
      <email>e.hoogervorst@antoniusziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeinstra</last_name>
      <email>ZEINSTRAE@isala.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Zoé van Kempen</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Natalizumab</keyword>
  <keyword>Extended interval dosing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

